ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 984,93
-0,99%
Dow Jones
37 815,92
-1,49%
DAX
17 932,17
-1,10%
Brent Oil
85,57
-0,38%
Bitcoin
60 196,93
-0,66%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Agenus Inc (AGEN)

  7. Agenus Inc (AGEN) Actualités

AGEN

Agenus (AGEN)

Agenus Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:AGEN
DateHeureSourceTitreSymboleSociété
24/04/202416h00Business WireBotensilimab/Balstilimab Data in MSS CRC Selected for the American Society of Clinical Oncology 2024 Annual MeetingNASDAQ:AGENAgenus Inc
23/04/202413h30Business WireAgenus to Provide First Quarter 2024 Financial Report and Corporate UpdateNASDAQ:AGENAgenus Inc
12/04/202413h30Business WireAgenus Announces Updated Phase 1 Data and Progress on BOT/BAL Development in Metastatic MSS Colorectal CancerNASDAQ:AGENAgenus Inc
05/04/202422h30Business WireAgenus Announces Reverse Stock Split of Common StockNASDAQ:AGENAgenus Inc
14/03/202412h30Business WireAgenus Reports Fourth Quarter and Full Year 2023 ResultsNASDAQ:AGENAgenus Inc
06/03/202413h30Business WireAgenus Announces Preclinical Data on BMS-986442 (AGEN1777) at AACR 2024NASDAQ:AGENAgenus Inc
05/03/202422h30Business WireAgenus Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:AGENAgenus Inc
29/02/202422h50Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:AGENAgenus Inc
29/02/202413h30Business WireAgenus to Provide Corporate Update and Fourth Quarter & Full Year 2023 Financial ReportNASDAQ:AGENAgenus Inc
26/02/202422h24Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:AGENAgenus Inc
26/02/202413h30Business WireAgenus to Participate in Leerink Partners Global Biopharma ConferenceNASDAQ:AGENAgenus Inc
15/02/202414h02Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:AGENAgenus Inc
15/02/202414h00Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:AGENAgenus Inc
15/02/202413h02PR Newswire (US)Ginkgo Bioworks and SaponiQx Awarded MCDC Contract to Discover and Manufacture Next-Generation Vaccine Adjuvants Using Generative Molecular DesignNASDAQ:AGENAgenus Inc
14/02/202414h33Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:AGENAgenus Inc
12/02/202413h00Edgar (US Regulatory)Form 5 - Annual statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
31/01/202413h30Business WireAgenus to Participate in Oppenheimer 34th Annual Healthcare Life Sciences ConferenceNASDAQ:AGENAgenus Inc
22/01/202415h59Business WireBotensilimab/Balstilimab Breakthrough Data Presented at ASCO-GI Shows Unprecedented Tumor Shrinkage and Robust Biomarker Response in Prevalent Colorectal Cancer PopulationNASDAQ:AGENAgenus Inc
04/01/202413h30Business WireAgenus to Participate in B. Riley Healthcare ConferenceNASDAQ:AGENAgenus Inc
04/01/202412h06Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:AGENAgenus Inc
20/12/202313h30Business WireBotensilimab/Balstilimab Data in Neoadjuvant Colorectal Cancer Selected for ASCO-GI 2024NASDAQ:AGENAgenus Inc
11/12/202313h30Business WireAgenus to Receive $25 Million Milestone Payment from Bristol Myers Squibb for TIGIT-CD96 Bispecific ProgramNASDAQ:AGENAgenus Inc
09/11/202322h11Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:AGENAgenus Inc
07/11/202312h30Business WireAgenus Reports Third Quarter 2023 ResultsNASDAQ:AGENAgenus Inc
26/10/202315h05Business WireAgenus to Provide Third Quarter 2023 Financial Report and Corporate UpdateNASDAQ:AGENAgenus Inc
22/10/202318h00Business WireAgenus Unveils New and Updated Botensilimab Data in Colorectal, Pancreatic, Lung, Melanoma, and SarcomaNASDAQ:AGENAgenus Inc
21/10/202310h15Business WireESMO 2023: Agenus’ Botensilimab/Balstilimab Combination Delivers Durable Responses across Multiple Sarcoma SubtypesNASDAQ:AGENAgenus Inc
10/10/202313h30Business WireAgenus Completes Enrollment in Randomized Phase 2 Clinical Trial of Botensilimab/Balstilimab in Advanced Colorectal CancerNASDAQ:AGENAgenus Inc
05/10/202313h30Business WireAgenus To Host BOT/BAL Program Update at ESMO 2023NASDAQ:AGENAgenus Inc
28/08/202313h30Business WireAgenus to Participate in September Investor ConferencesNASDAQ:AGENAgenus Inc
 Showing the most relevant articles for your search:NASDAQ:AGEN

Dernières Valeurs Consultées

EU
ML
Michelin
EU
HO
Thales
NASDAQ
GOOGL
Alphabet
EU
CS
Axa
EU
ACA
Credit Agricole
COIN
BTCUSD
Bitcoin
EU
AF
Air FranceKLM
EU
BNP
BNP Paribas
NYSE
NKE
Nike
NASDAQ
AAPL
Apple
EU
SGO
Cie de SaintGobain
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés